Spectrascience New Financials
Based on the key measurements obtained from Spectrascience New's financial statements, Spectrascience New may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At present, Spectrascience New's Total Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Accounts Payable is expected to grow to about 1.6 M, whereas Total Stockholder Equity is projected to grow to (9 M). Key indicators impacting Spectrascience New's financial strength include:
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.0366 | 0.0385 |
|
|
The essential information of the day-to-day investment outlook for Spectrascience New includes many different criteria found on its balance sheet. An individual investor should monitor Spectrascience New's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Spectrascience New.
Net Income |
|
Spectrascience | Select Account or Indicator |
Understanding current and past Spectrascience New Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Spectrascience New's financial statements are interrelated, with each one affecting the others. For example, an increase in Spectrascience New's assets may result in an increase in income on the income statement.
Please note, the presentation of Spectrascience New's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Spectrascience New's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Spectrascience New's management manipulating its earnings.
Spectrascience New Stock Summary
SpectraScience, Inc. develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy in the United States, Europe, and internationally. SpectraScience, Inc. was founded in 1983 and is based in San Diego, California. Spectrascience operates under Medical Appliances Equipment classification in the United States and is traded on OTC Exchange. It employs 5 people.Specialization | Health Care, Health Care Equipment & Services |
| Instrument | USA Stock View All |
| Exchange | OTCCE Exchange |
| ISIN | US84760E3018 |
| Business Address | 11568 Sorrento Valley |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.spectrascience.com |
| Phone | 858 847 0200 |
| Currency | USD - US Dollar |
Spectrascience New Key Financial Ratios
| Price To Sales | 73.07 X | ||||
| Revenue | 5.15 K | ||||
| Gross Profit | (194.25 K) | ||||
| Net Income | (4.47 M) | ||||
| Current Ratio | 0.02 X |
Spectrascience Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Spectrascience New's current stock value. Our valuation model uses many indicators to compare Spectrascience New value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Spectrascience New competition to find correlations between indicators driving Spectrascience New's intrinsic value. More Info.Spectrascience New is currently regarded as top stock in return on asset category among its peers. It also is currently regarded number one company in current valuation category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Spectrascience New by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Spectrascience New Systematic Risk
Spectrascience New's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Spectrascience New volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Spectrascience New correlated with the market. If Beta is less than 0 Spectrascience New generally moves in the opposite direction as compared to the market. If Spectrascience New Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Spectrascience New is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Spectrascience New is generally in the same direction as the market. If Beta > 1 Spectrascience New moves generally in the same direction as, but more than the movement of the benchmark.
About Spectrascience New Financials
What exactly are Spectrascience New Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Spectrascience New's income statement, its balance sheet, and the statement of cash flows. Potential Spectrascience New investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Spectrascience New investors may use each financial statement separately, they are all related. The changes in Spectrascience New's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Spectrascience New's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Today, most investors in Spectrascience New Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Spectrascience New's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Spectrascience New growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Complementary Tools for Spectrascience Stock analysis
When running Spectrascience New's price analysis, check to measure Spectrascience New's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spectrascience New is operating at the current time. Most of Spectrascience New's value examination focuses on studying past and present price action to predict the probability of Spectrascience New's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spectrascience New's price. Additionally, you may evaluate how the addition of Spectrascience New to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |